Search Results - "ASSENAT, Eric"

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC by Lencioni, Riccardo, Montal, Robert, Torres, Ferran, Park, Joong-Won, Decaens, Thomas, Raoul, Jean-Luc, Kudo, Masatoshi, Chang, Charissa, Ríos, José, Boige, Valerie, Assenat, Eric, Kang, Yoon-Koo, Lim, Ho-Yeong, Walters, Ian, Llovet, Josep M

“…Graphical abstract…”
Get full text

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study by Edeline, Julien, Benabdelghani, Meher, Bertaut, Aurélie, Watelet, Jérôme, Hammel, Pascal, Joly, Jean-Paul, Boudjema, Karim, Fartoux, Laetitia, Bouhier-Leporrier, Karine, Jouve, Jean-Louis, Faroux, Roger, Guerin-Meyer, Véronique, Kurtz, Jean-Emmanuel, Assénat, Eric, Seitz, Jean-François, Baumgaertner, Isabelle, Tougeron, David, de la Fouchardière, Christelle, Lombard-Bohas, Catherine, Boucher, Eveline, Stanbury, Trevor, Louvet, Christophe, Malka, David, Phelip, Jean-Marc

“…No standard adjuvant treatment currently is recommended in localized biliary tract cancer (BTC) after surgical resection. We aimed to assess whether…”
Get full text

Establishment and characterization of a cell line from human circulating colon cancer cells by Cayrefourcq, Laure, Mazard, Thibault, Joosse, Simon, Solassol, Jérôme, Ramos, Jeanne, Assenat, Eric, Schumacher, Udo, Costes, Valérie, Maudelonde, Thierry, Pantel, Klaus, Alix-Panabières, Catherine

“…Circulating tumor cells (CTC) in blood are promising new biomarkers potentially useful for prognostic prediction and monitoring of therapies in patients with…”
Get full text

Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial by Garin, Etienne, Tselikas, Lambros, Guiu, Boris, Chalaye, Julia, Edeline, Julien, de Baere, Thierry, Assenat, Eric, Tacher, Vania, Robert, Corentin, Terroir-Cassou-Mounat, Marie, Mariano-Goulart, Denis, Amaddeo, Giuliana, Palard, Xavier, Hollebecque, Antoine, Kafrouni, Marilyne, Regnault, Hélène, Boudjema, Karim, Grimaldi, Serena, Fourcade, Marjolaine, Kobeiter, Hicham, Vibert, Eric, Le Sourd, Samuel, Piron, Lauranne, Sommacale, Danièle, Laffont, Sophie, Campillo-Gimenez, Boris, Rolland, Yan

“…All randomised phase 3 studies of selective internal radiation therapy for advanced hepatocellular carcinoma published to date have reported negative results…”
Get more information

Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial by Assenat, Eric, Pageaux, Georges-Philippe, Thézenas, Simon, Peron, Jean-Marie, Bécouarn, Yves, Seitz, Jean-François, Merle, Philippe, Blanc, Jean-Frédéric, Bouché, Olivier, Ramdani, Mohamed, Poujol, Sylvain, de Forges, Hélène, Ychou, Marc, Boige, Valérie

“…Background Sorafenib remains one major first-line therapeutic options for advanced hepatocellular carcinoma (aHCC), with modest efficacy. We investigated the…”
Get full text

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study by LLOVET, Josep M, DECAENS, Thomas, MATHURIN, Philippe, FARTOUX, Laetitia, LIN, Deng-Yn, BRUIX, Jordi, POON, Ronnie T, SHERMAN, Morris, BLANC, Jean-Frédéric, FINN, Richard S, TAK, Won-Young, YEE CHAO, RAOUL, Jean-Luc, EZZEDDINE, Rana, LIU, David, WALTERS, Ian, PARK, Joong-Won, BOUCHER, Eveline, KUDO, Masatoshi, CHANG, Charissa, KANG, Yoon-Koo, ASSENAT, Eric, LIM, Ho-Yeong, BOIGE, Valerie

“…Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors implicated in tumorigenesis and…”
Get full text

Molecular Portrait of Metastasis-Competent Circulating Tumor Cells in Colon Cancer Reveals the Crucial Role of Genes Regulating Energy Metabolism and DNA Repair by Alix-Panabières, Catherine, Cayrefourcq, Laure, Mazard, Thibault, Maudelonde, Thierry, Assenat, Eric, Assou, Said

“…Unraveling the molecular mechanisms that regulate the biology of metastasis-competent circulating tumor cells (CTCs) is urgently needed to understand…”
Get full text

A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH) by Deshayes, Emmanuel, Assenat, Eric, Meignant, Laetitia, Bardiès, Manuel, Santoro, Lore, Gourgou, Sophie

“…Although neuroendocrine tumors (NET) are classed as rare, they have a high prevalence and their incidence is increasing. Effective treatment with lutetium…”
Get full text

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial by Malka, David, Dr, Cervera, Pascale, MD, Foulon, Stéphanie, MSc, Trarbach, Tanja, MD, de la Fouchardière, Christelle, MD, Boucher, Eveline, MD, Fartoux, Laetitia, MD, Faivre, Sandrine, Prof, Blanc, Jean-Frédéric, Prof, Viret, Frédéric, MD, Assenat, Eric, MD, Seufferlein, Thomas, Prof, Herrmann, Thomas, Prof, Grenier, Julien, MD, Hammel, Pascal, Prof, Dollinger, Matthias, MD, André, Thierry, Prof, Hahn, Philipp, MD, Heinemann, Volker, Prof, Rousseau, Vanessa, PhD, Ducreux, Michel, Prof, Pignon, Jean-Pierre, MD, Wendum, Dominique, Prof, Rosmorduc, Olivier, Prof, Greten, Tim F, Prof

“…Summary Background Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the standard of care for advanced biliary cancers. We investigated…”
Get full text

Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [ 177 Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine by Hebert, Kévin, Santoro, Lore, Monnier, Maeva, Castan, Florence, Berkane, Ikrame, Assénat, Eric, Fersing, Cyril, Gélibert, Pauline, Pouget, Jean-Pierre, Bardiès, Manuel, Kotzki, Pierre-Olivier, Deshayes, Emmanuel

“…[ Lu]Lu-DOTATATE has been approved for progressive and inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that overexpress somatostatin…”
Get full text

Selective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones by Cayrefourcq, Laure, Thomas, Frédéric, Mazard, Thibault, Assenat, Eric, Assou, Said, Alix-Panabières, Catherine

“…The characterization of circulating tumor cells (CTCs) holds promises for precision medicine because these cells are an important clinical indicator of…”
Get full text

Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab by Zhu, Andrew X., Finn, Richard S., Kang, Yoon-Koo, Yen, Chia-Jui, Galle, Peter R., Llovet, Josep M., Assenat, Eric, Brandi, Giovanni, Motomura, Kenta, Ohno, Izumi, Daniele, Bruno, Vogel, Arndt, Yamashita, Tatsuya, Hsu, Chih-Hung, Gerken, Guido, Bilbruck, John, Hsu, Yanzhi, Liang, Kun, Widau, Ryan C., Wang, Chunxiao, Abada, Paolo, Kudo, Masatoshi

“…Background Post hoc analyses assessed the prognostic and predictive value of baseline alpha-fetoprotein (AFP), as well as clinical outcomes by AFP response or…”
Get full text

Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes by Soler, Alexandra, Cayrefourcq, Laure, Mazard, Thibault, Babayan, Anna, Lamy, Pierre-Jean, Assou, Said, Assenat, Eric, Pantel, Klaus, Alix-Panabières, Catherine

“…Circulating tumor cells (CTCs) are important clinical indicators for prognosis and treatment efficacy. However, CTC investigation is hampered by their low…”
Get full text

Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury, as assessed for causality using the updated RUCAM by Hountondji, Lina, Faure, Stéphanie, Palassin, Pascale, Viel, Philine Witkowski Durand, Dupuy, Marie, Larrey, Dominique, Lamoureux, Anouck, Coustal, Cyrille, Pureur, Dimitri, Lesage, Candice, Assenat, Éric, Rivière, Benjamin, Faillie, Jean-Luc, Quantin, Xavier, Pageaux, Georges-Philippe, Maria, Alexandre Thibault Jacques, Meunier, Lucy

“…While immune checkpoint inhibitors (ICIs) are revolutionising cancer therapy, checkpoint inhibitor-induced liver injury is a significant immune-related side…”
Get full text

Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial by Garin, Etienne, Tselikas, Lambros, Guiu, Boris, Chalaye, Julia, Rolland, Yan, de Baere, Thierry, Assenat, Eric, Tacher, Vania, Palard, Xavier, Déandreis, Desirée, Mariano-Goulart, Denis, Amaddeo, Giuliana, Boudjema, Karim, Hollebecque, Antoine, Meerun, Mohamad Azhar, Regnault, Helen, Vibert, Eric, Campillo-Gimenez, Boris, Edeline, Julien

“…Interim analysis of the DOSISPHERE-01 study demonstrated a strong improvement in response and overall survival (OS) on using Y-loaded glass microspheres with…”
Get full text

Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial by Ychou, Marc, Rivoire, Michel, Thezenas, Simon, Guimbaud, Rosine, Ghiringhelli, Francois, Mercier-Blas, Anne, Mineur, Laurent, Francois, Eric, Khemissa, Faiza, Chauvenet, Marion, Kianmanesh, Reza, Fonck, Marianne, Houyau, Philippe, Aparicio, Thomas, Galais, Marie-Pierre, Audemar, Franck, Assenat, Eric, Lopez-Crapez, Evelyne, Jouffroy, Claire, Adenis, Antoine, Adam, René, Bouché, Olivier

“…Background Colorectal cancer (CRC) patients have a better prognosis if metastases are resectable. Initially, unresectable liver-only metastases can be…”
Get full text

NOD1 Participates in the Innate Immune Response Triggered by Hepatitis C Virus Polymerase by Vegna, Serena, Gregoire, Damien, Moreau, Marie, Lassus, Patrice, Durantel, David, Assenat, Eric, Hibner, Urszula, Simonin, Yannick

“…Hepatitis C virus (HCV) triggers innate immunity signaling in the infected cell. Replication of the viral genome is dispensable for this phenotype, and we…”
Get full text

Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial by Merle, Philippe, Blanc, Jean-Frédéric, Edeline, Julien, Le Malicot, Karine, Allaire, Manon, Assenat, Eric, Guarssifi, Meriem, Bouattour, Mohamed, Péron, Jean-Marie, Laurent-Puig, Pierre, Levrero, Massimo, Costentin, Charlotte, Guiu, Boris, Sokol, Harry, Tougeron, David, Aparicio, Thomas, Nault, Jean-Charles, Phelip, Jean-Marc

“…A substantial proportion of patients with hepatocellular carcinoma have to face up, sooner or later, to systemic therapy. The current standards as first line…”
Get full text

FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis by Ursic-Bedoya, José, Desandré, Guillaume, Chavey, Carine, Marie, Pauline, Polizzi, Arnaud, Rivière, Benjamin, Guillou, Hervé, Assenat, Eric, Hibner, Urszula, Gregoire, Damien

“…FGF19 hormone has pleiotropic metabolic functions, including the modulation of insulin sensitivity, glucose/lipid metabolism and energy homeostasis. On top of…”
Get full text

Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication by Faure, Stéphanie, Herrero, Astrid, Jung, Boris, Duny, Yohan, Daures, Jean-Pierre, Mura, Thibaut, Assenat, Eric, Bismuth, Michaël, Bouyabrine, Hassan, Donnadieu-Rigole, Hélène, Navarro, Francis, Jaber, Samir, Larrey, Dominique, Pageaux, Georges-Philippe

“…Background & Aims Beyond 5 years, poorer survival, related to alcohol relapse, is observed in patients with liver transplant for alcohol-related liver disease…”
Get full text